Latest results from the phase III IKEMA clinical trial evaluating the monoclonal antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (HR: 0.58; 95% CI: 25.8-44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8-25.1; n=123), in patients with relapsed multiple myeloma.
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.
